Trials / Completed
CompletedNCT03703570
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
A Phase 2b Study of KW-6356 in Subjects With Parkinson's Disease on Treatment With Levodopa-containing Preparations
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 502 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the recommended dose and evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) partIII score between KW-6356 and placebo in patients with Parkinson's disease on treatment with Levodopa-containing preparations as an adjunctive therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KW-6356 | Oral administration |
| DRUG | Placebo | Oral administration |
Timeline
- Start date
- 2018-09-29
- Primary completion
- 2020-04-15
- Completion
- 2020-04-15
- First posted
- 2018-10-12
- Last updated
- 2020-09-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03703570. Inclusion in this directory is not an endorsement.